Photochemical Inactivation of Bacteria and HIV in Buffy–Coat–Derived Platelet Concentrates under Conditions That Preserve in vitro Platelet Function

Background and Objectives: A photochemical process has been tested for the inactivation of viruses and bacteria in buffy–coat derived platelet concentrates (BC PCs). Materials and Methods: BC PCs in 35% CPD plasma and 65% platelet–additive solution (PAS III) were exposed to photochemical treatment (PCT) with 150 μM of the psoralen S–59 and a 3 J/cm2 treatment with long–wavelength ultraviolet light (UVA, 320–400 nm). Platelet function was evaluated following PCT using a panel of in vitro assays. Results: This PCT process was highly effective at inactivating gram–positive bacteria (Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus faecalis) and gram–negative bacteria (Enterobacter aerogenes, Pseudomonas aeruginosa, Serratia marcescens). No viable bacteria were detected following PCT and 7 days of platelet storage while bacterial growth was detected in paired untreated control BC PCs. Complete inactivation of the gram–positive Bacillus cereus was achieved only in one of two replicate experiments with BC PCs. PCT was also highly effective for inactivation of human immunodeficiency virus HIV–1 in BC PCs inoculated with approximately 106 tissue culture infectious doses per milliliter (TCID50/ml) of cell–associated HIV–1. Rapid inactivation was observed with increasing UVA doses: with 150 μM S–59 and a 1 J/cm2 treatment of UVA, a reduction of 5.6±0.5 log TCID50/ml was achieved, and a reduction of >6.4 log TCID50/ml was achieved with 150 μM S–59 and a 3 J/cm2 treatment of UVA. No physiologically relevant differences in platelet functions were found between the test and the control BC PCs during 7 days of storage. Conclusion: PCT with 150 μM S–59 and a 3 J/cm2 UVA treatment does not adversely affect in vitro properties of BC PCs stored at 22°C for 7 days. The PCT process inactivated bacteria and HIV–1 inoculated into the BC PCs. These results extend the earlier reported efficacy of PCT apheresis PCs to BC PCs.

[1]  M. Ríos HIV and Blood Transfusion , 2001 .

[2]  L. Corash,et al.  Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. , 1999, Blood.

[3]  L. Corash,et al.  Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light , 1999, Transfusion.

[4]  L. Corash,et al.  Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. , 1998, Blood.

[5]  J. Hearst,et al.  Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long‐wavelength ultraviolet light , 1997, Transfusion.

[6]  M. Blajchman,et al.  The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes. , 1997, Transfusion medicine reviews.

[7]  J. Bring,et al.  Evaluation of Platelet Function Using the in vitro Bleeding Time and Corrected Count Increment of Transfused Platelets: Comparison between Platelet Concentrates Derived from Pooled Buffy Coates and Apheresis , 1996, Vox sanguinis.

[8]  C. Högman ADVERSE EFFECTS: BACTERIAL CONTAMINATION (INCLUDING SHELF LIFE). , 1996 .

[9]  S. Shafer,et al.  The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans. , 1995, British journal of clinical pharmacology.

[10]  Yun-Fai Chris Lau,et al.  A prospective study of symptomatic bacteremia following platelet transfusion and of its management , 1994, Transfusion.

[11]  M. Busch HIV AND BLOOD TRANSFUSIONS: FOCUS ON SEROCONVERSION , 1994, Vox sanguinis.

[12]  M. Blajchman,et al.  BACTERIAL CONTAMINATION OF CELLULAR BLOOD COMPONENTS , 1994, Vox sanguinis.

[13]  L. Corash,et al.  Photochemical inactivation of pathogenic bacteria in human platelet concentrates. , 1994, Blood.

[14]  M. Lundholm,et al.  Novel automated microbial screening of platelet concentrates , 1994, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[15]  L. Corash,et al.  Photochemical inactivation of cell-associated human immunodeficiency virus in platelet concentrates. , 1993, Blood.

[16]  C. Hogman,et al.  White cells protect donor blood against bacterial contamination , 1991, Transfusion.

[17]  Laurence Corash,et al.  Use of 8-methoxypsoralen and long-wavelength ultraviolet radiation for decontamination of platelet concentrates , 1989, Photonics West - Lasers and Applications in Science and Engineering.

[18]  P. Holland Prevention of transfusion-associated graft-vs-host disease. , 1989, Archives of pathology & laboratory medicine.

[19]  L. Corash,et al.  PHOTOCHEMICAL DECONTAMINATION OF BLOOD COMPONENTS CONTAINING HEPATITIS B AND NON-A, NON-B VIRUS , 1988, The Lancet.

[20]  C. Högman,et al.  The Bottom and Top System: A New Technique for Blood Component Preparation and Storage , 1988, Vox sanguinis.

[21]  S. Holme,et al.  Improved in vivo and in vitro viability of platelet concentrates stored for seven days in a platelet additive solution , 1987, British journal of haematology.

[22]  J. Hearst,et al.  Psoralen-deoxyribonucleic acid photoreaction. Characterization of the monoaddition products from 8-methoxypsoralen and 4,5'8-trimethylpsoralen. , 1982, Biochemistry.

[23]  S. Murphy,et al.  Quantitative measurements of platelet shape by light transmission studies; application to storage of platelets for transfusion. , 1978, The Journal of laboratory and clinical medicine.

[24]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[25]  P. Rebulla,et al.  In vitro assessment of the quality of stored platelet concentrates. The BEST (Biomedical Excellence for Safer Transfusion) Task Force of the International Society of Blood Transfusion. , 1994, Transfusion medicine reviews.

[26]  C. Högman,et al.  Leukocyte-depleted platelets prepared from pooled buffy coat post-transfusion increment and "in vitro bleeding time" using the Thrombostat 4000/2. , 1993, Transfusion science.